Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT00857714
Status
Terminated

Conditions

  • Ductal Carcinoma in Situ

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib — DRUG
    1500 mg lapatinib for 14-21 days

Study Details

The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.

Key Dates

Start date
Apr 30, 2009
Status verified
Jun 2015
Primary completion
Aug 31, 2010
Completion
Aug 31, 2010

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Primary Outcome Measure

Number of Patients Where Gene Signature Was Obtained. [ Time Frame: Up to 60 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana UniversityIndianapolisIndiana46202-

Find similar trials in Indianapolis, IN

By research site
Indiana University· Indianapolis, IN

Related Studies